These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1146 related articles for article (PubMed ID: 8938145)

  • 1. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3.
    Fleischhauer K; Fruci D; Van Endert P; Herman J; Tanzarella S; Wallny HJ; Coulie P; Bordignon C; Traversari C
    Int J Cancer; 1996 Nov; 68(5):622-8. PubMed ID: 8938145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44.
    Luescher IF; Romero P; Kuznetsov D; Rimoldi D; Coulie P; Cerottini JC; Jongeneel CV
    J Biol Chem; 1996 May; 271(21):12463-71. PubMed ID: 8647853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
    Herman J; van der Bruggen P; Luescher IF; Mandruzzato S; Romero P; Thonnard J; Fleischhauer K; Boon T; Coulie PG
    Immunogenetics; 1996; 43(6):377-83. PubMed ID: 8606058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
    Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
    Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid.
    Herman J; Jongeneel V; Kuznetsov D; Coulie PG
    Tissue Antigens; 1999 Feb; 53(2):111-21. PubMed ID: 10090611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.
    Bilsborough J; Panichelli C; Duffour MT; Warnier G; Lurquin C; Schultz ES; Thielemans K; Corthals J; Boon T; van der Bruggen P
    Tissue Antigens; 2002 Jul; 60(1):16-24. PubMed ID: 12366779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
    van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
    Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
    Luiten RM; Demotte N; Tine J; van der Bruggen P
    Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
    Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
    J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
    Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
    Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family.
    Tanzarella S; Russo V; Lionello I; Dalerba P; Rigatti D; Bordignon C; Traversari C
    Cancer Res; 1999 Jun; 59(11):2668-74. PubMed ID: 10363990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.
    Brichard VG; Herman J; Van Pel A; Wildmann C; Gaugler B; Wölfel T; Boon T; Lethé B
    Eur J Immunol; 1996 Jan; 26(1):224-30. PubMed ID: 8566071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.
    Chames P; Hufton SE; Coulie PG; Uchanska-Ziegler B; Hoogenboom HR
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7969-74. PubMed ID: 10884427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population.
    DiBrino M; Parker KC; Margulies DH; Shiloach J; Turner RV; Biddison WE; Coligan JE
    Biochemistry; 1995 Aug; 34(32):10130-8. PubMed ID: 7543776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.
    Schultz ES; Chapiro J; Lurquin C; Claverol S; Burlet-Schiltz O; Warnier G; Russo V; Morel S; Lévy F; Boon T; Van den Eynde BJ; van der Bruggen P
    J Exp Med; 2002 Feb; 195(4):391-9. PubMed ID: 11854353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones.
    Fleischhauer K; Tanzarella S; Russo V; Sensi ML; van der Bruggen P; Bordignon C; Traversari C
    J Immunol; 1997 Sep; 159(5):2513-21. PubMed ID: 9278345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
    Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
    Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.